Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5701523 | Journal of Thoracic Oncology | 2017 | 34 Pages |
Abstract
The prevalence of METex14 skipping was quite high in East Asian patients without other driver mutations in lung adenocarcinomas. METex14 skipping was associated with old age, the acinar or solid histologic subtype, and high MET immunohistochemical expression. The prognosis of patients with METex14 skipping was similar to that of patients with major driver mutations. siRNA targeting the junction of METex14 skipping could inhibit MET-driven signaling pathways in cells with METex14 skipping.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Geun Dong MD, PhD, Seung Eun MD, PhD, Doo-Yi PhD, Dan-bi MS, Hae Min PhD, Jooseok BS, Sungyoul PhD, Hun Soon PhD, Ensel PhD, Ji-Young MS, Mi-Sook PhD, Mingi BS, Kyungsoo BS, Jhingook MD, Young Kee MD, PhD, Yoon-La MD, PhD, Hyeong Ryul MD, PhD,